Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Citalopram treatment of fluoxetine nonresponders
Autore:
Thase, ME; Feighner, JP; Lydiard, RB;
Indirizzi:
Med Univ S Carolina, Charleston, SC 29425 USA Med Univ S Carolina Charleston SC USA 29425 ina, Charleston, SC 29425 USA Feighner Res Inst, San Diego, CA USA Feighner Res Inst San Diego CA USAFeighner Res Inst, San Diego, CA USA Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA Univ Pittsburgh Pittsburgh PA USA Med, Dept Psychiat, Pittsburgh, PA USA
Titolo Testata:
JOURNAL OF CLINICAL PSYCHIATRY
fascicolo: 9, volume: 62, anno: 2001,
pagine: 683 - 687
SICI:
0160-6689(200109)62:9<683:CTOFN>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
SEROTONIN REUPTAKE INHIBITORS; ANTIDEPRESSANTS; SERTRALINE; RECEPTOR; SSRIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Thase, ME Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA Western Psychiat Inst & Clin 3811 OHara St Pittsburgh PA USA 15213
Citazione:
M.E. Thase et al., "Citalopram treatment of fluoxetine nonresponders", J CLIN PSY, 62(9), 2001, pp. 683-687

Abstract

Background: We assessed the tolerability and utility of switching fluoxetine nonresponders to citalopram the day that fluoxetine therapy was stopped. Method: Fifty-eight outpatients with DSM-IV major depressive episode and prospectively confirmed nonresponse to fluoxetine (mean final dose = 31 mg/day) were switched directly to citalopram (20 mg/day). Of the 58 patients, 44 (76%) had never been successfully treated with antidepressant medication. During a 12-week open-label treatment period, citalopram could be titratedup to a maximum dose of 60 mg/day. Response was evaluated using the Clinical Global Impressions (CGI) scale, the 24-item Hamilton Rating Scale for Depression, and several other measures. Results: Eighty-one percent (N = 47) completed the trial, and citalopram (mean dose = 38.8 mg/day) was well tolerated. The intent-to-treat CGI response rate was 46% (26/57) at week 6 and 63% (36/57) at study endpoint; the completer response rate was 76% among the 47 patients who completed the 12-week trial. Improvement from baseline on all dependent measures was statistically significant after the first week of citalopram treatment. Conclusion: Fluoxetine nonresponders can be quickly switched to citalopram, with good tolerability and reasonable chance of therapeutic benefit. Further work is necessary to assess the merits of this treatment strategy relative to other options.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 18:37:11